close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Gossamer Bio, Inc.

< Previous 1 2 Next >
News headline image
Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Announces 1-for-80 Reverse Stock Split
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio to Present at Cantor Global Healthcare Conference
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio to Participate in Upcoming Investor Conferences
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio to Participate in Upcoming Investor Conferences
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio to Present at Upcoming Investor Conferences
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
News headline image
Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Tickers GOSS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.